Update on the functional biology of Lrrk2

Future Neurology

Volumn 3, Issue 6, 2008, Pages 669-681

  Melrose, Heather ^a  

^a MAYO CLINIC   (United States)

Author keywords

GTPase; Kinase; LRRK2; Models; Neurodegeneration; Neurogenesis; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; AMINO ACID; DJ 1 PROTEIN; GUANINE NUCLEOTIDE BINDING PROTEIN; GUANOSINE TRIPHOSPHATASE; LEUCINE RICH REPEAT KINASE 2; PARKIN; PROTEASOME; PROTEIN KINASE; UBIQUITIN;

AMINO ACID SUBSTITUTION; CELLULAR DISTRIBUTION; DEGENERATIVE DISEASE; GENE LOCUS; GENE MUTATION; GENETIC LINKAGE; GENETIC RISK; GENETIC SUSCEPTIBILITY; HUMAN; MOLECULAR BIOLOGY; MUTATIONAL ANALYSIS; NEUROPATHOLOGY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION;

EID: 67149108177     PISSN: 14796708     EISSN: None     Source Type: Journal    
DOI: 10.2217/14796708.3.6.669     Document Type: Review

References (94)

1. Paisan-Ruiz C, Jain S, Evans EW et al.: Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease. Neuron 44, 595-600 (2004).
2. Funayama M, Hasegawa K, Kowa H et al.: A new locus for Parkinson's disease (PARK8) maps, to chromosome 12p11.2-q131. Ann. Neurol. 51, 296-301 (2002).
3. Zimprich A, Biskup S, Leitner P et al.: Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 44, 601-607 (2004).
4. Kachergus J, Mata IF, Hulihan M et al.: Identification of a novel LRRK2 mutation linked to autosomal dominant parkinsonism: evidence of a common founder across European populations. Am. J. Hum. Genet. 76, 672-680 (2005).
5. Funayama M, Hasegawa K, Ohta E et al.: An LRRK2 mutation as a cause for the parkinsonism in the original PARK8 family. Ann. Neurol. 57, 918-921 (2005).
6. Hernandez D, Paisan Ruiz C, Crawley A et al.: The dardarin G 2019 S mutation is a common cause of Parkinson's disease but not other neurodegenerative diseases. Neurosci. Lett. 389, 137-139 (2005).
7. Mata IF, Kachergus JM, Taylor JP et al.: Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics 6, 171-177 (2005).
8. Healy DG, Falchi M, O'Sullivan SS et al.: Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study. Lancet Neurol. 7, 583-590 (2008).
9. Ozelius LJ, Senthil G, Saunders-Pullman R et al.: LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews. N. Engl. J. Med. 354, 424-425 (2006).
10. Ishihara L, "Warren L, Gibson R et al.: Clinical features of Parkinson disease patients with homozygous leucine-rich repeat kinase 2 G2019S mutations. Arch. Neurol. 63, 1250-1254 (2006).
11. Lesage S, Durr A, Tazir M et al.: LKRK2 G2019S as a cause of Parkinson's disease in North African Arabs. N. Engl. J. Med. 354, 422-423 (2006).
12. Di Fonzo A, Wu-Chou YH, Lu CS et al.: A common missense variant in the LRRK2 gene Gly2385Arg, associated with Parkinson's disease risk in Taiwan. Neurogenetics 7, 133-138 (2006).
13. Farrer MJ, Stone JT, Lin CH et al.: Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia. Parkinsonism Relat. Disord. 13, 89-92 (2007).
14. Ross OA, Wu YR, Lee MC et al.: Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease. Ann. Neurol. 64(1), 88-92 (2008).
15. Ross OA, Toft M, Whittle AJ et al.: Lrrk2 and Lewy body disease. Ann. Neurol. 59, 388-393 (2006).
16. Dachsel JC, Ross OA, Mata IF et al.: Lrrk2 G2019S substitution in frontotemporal lobar degeneration with ubiquitin-immunoreactiye neuronal inclusions. Acta Neuropathol. (Berl.) 113, 601-606 (2007).
17. Rajput A, Dickson DW, Robinson CA et al.: Parkinsonism Lrr2 G2012S, and tau neuropathology. Neurology 67, 1506-1508 (2006).
18. Taylor JP, Mata IF, Farrer MJ: LRRK2: a common pathway for parkinsonism, pathogenesis and prevention? Trends Mol. Med. 7, 7 (2006).
19. Wszolek ZK, Pfeiffer RF, Tsuboi Y et al.: Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology 62, 1619-1622 (2004).
20. Greggio E, Jain S, Kingsbury A et al.: Kinase activity is required for the toxic effects of mutant LRRK2/dardarin. Neurobiol. Dis. 23, 329-341 (2006).
21. Miklossy J, Arai T, Gud JP et al.: LRRK2 expression in normal and pathologic human brain and in human cell lines. J. Neuropathol. Exp. Neurol. 65, 953-963 (2006).
22. Zhu X, Babar A, Siedlak SL et al.: LRRK2 in Parkinson's disease and dementia with Lewy bodies. Mol. Neurodegener. 1, 17 (2006).
23. Zhu X, Siedlak SL, Smith MA, Perry G, Chen SG: LRRK2 protein is a component of lewy bodies. Ann. Neurol. 60, 617-618 (2006).
24. Giasson BI, Covy JP, Bonini NM et al.: Biochemical and pathological characterization of Lrrk2. Ann. Neurol. 59, 315-322 (2006).
25. Covy J, Van Deerlin V, Giasson B: Lack of evidence for Lrrk2 in α-synuclein pathological inclusions. Ann. Neurol. 60, 618-619 (2006).
26. Melrose H, Kent C, Taylor J et al.: A comparative analysis of Lrrk2 expression in mouse brain and Lewy body disease. Neuroscience 147(4), 1047-1058 (2007).
27. Perry G, Zhu X, Babar AK et al.: Leucine-rich repeat kinase 2 colocalizes with α-synuclein in Parkinson's disease, but not tau-containing deposits in tauopathies. Neurodegener. Dis. 5, 222-224 (2008).
28. Bosgraaf L, Van Haastert PJ: Roc, a Ras/GTPase domain in complex proteins. Biochim. Biophys. Acta 7, 1-3 (2003).
29. Mata IF, Wedemeyer WJ, Fairer MJ, Taylor JP, Gallo KA: LRRK2 in Parkinson's disease: protein domains and functional insights. Trends Neurosci. 29, 286-293 (2006).
30. Taylor JP, Hulihan MM, Kachergus JM et al.: Leucine-rich repeat kinase 1: a paralog of LRRK2 and a candidate gene for Parkinson's disease. Neurogenetics 8, 95-102 (2007).
31. Biskup S, Moore DJ, Rea A et al.: Dynamic and redundant regulation of LRRK2 and LRRK1 expression. BMC Neurosci. 8, 102 (2007).
32. White LR, Toft M, Kvam SN, Farrer MJ, Aasly JO: MAPK-pathway activity, Lrrk2 G2019S, and Parkinson's disease. J. Neurosci. Res. 85, 1288-1294 (2007).
33. Li X, Tan YC, Poulose S et al.: Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants. J. Neurochem. 103 (1), 238-247 (2007).
34. Westerlund M, Belin AC, Anvret A et al.: Developmental regulation of leucine-rich repeat kinase 1 and 2 expression in the brain and other rodent and human organs: implications for Parkinson's disease. Neuroscience 152, 429-436 (2008).
35. Gaiter D, Westerlund M, Carmine A et al.: LRRK2 expression linked to dopamine-innervated areas. Ann. Neurol. 59, 714-719 (2006).
36. Melrose H, Lincoln S, Tyndall G, Dickson D, Farrer M: Anatomical localization of leucine-rich repeat kinase 2 in mouse brain. Neuroscience 139, 791-794 (2006).
37. Simon-Sanchez J, Herranz-Perez V, Olucha-Bordonau F, Perez-Tur J: LRRK2 is expressed in areas affected by Parkinson's disease in the adult mouse brain. Eur. J. Neurosci. 23, 659-666 (2006).
38. Taymans JM, Van den Haute C, Baekelandt V: Distribution of PINK1 and LRRK2 in rat and mouse brain. J. Neurochem. 98, 951-961 (2006).
39. Higashi S, Moore DJ, Colebrooke RE et al.: Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 100(2), 368-381 (2006).
40. Biskup S, Moore DJ, Celsi F et al.: Localization of LRRK2 to membranous and vesicular structures in mammalian brain. Ann. Neurol. 60, 557-569 (2006).
41. Greggio E, Lewis PA, van der Brug MP et al.: Mutations in LRRK2/ dardarin associated with Parkinson disease ate more toxic than equivalent mutations in the homologous kinase LRRK1. J. Neurochem. 102, 93-102 (2007).
42. Hurley MJ, Patel PH, Jackson MJ et al.: Striatal leucine-rich repeat kinase 2 mRNA is increased in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned common marmosets (Callithrix jacchus) with 1-3, 4-dihydroxyphenylalanine methyl ester-induced dyskinesia. Eur. J. Neurosci. 26, 171-177 (2007).
43. Higashi S, Moore DJ, Colebrooke RE et al.: Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain. J. Neurochem. 100, 368-381 (2007).
44. Gloeckner CJ, Kinkl N, Schumacher A et al.: The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity. Hum. Mol. Genet. 15, 223-232 (2006).
45. Madeod D, Dowman J, Hammond R et al.: The familial parkinsonism gene LRRK2 regulates neurite process morphology. Neuron 52, 587-593 (2006).
46. West AB, Moore DJ, Biskup S et al.: Parkinson s disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. Proc. Natl Acad. Sci. USA 102, 16842-16847 (2005).
47. Smith WW, Pei Z, Jiang H et al.: Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nat. Neurosci. 9, 1231-1233 (2006).
48. Hatano T, Kubo S, Imai S et al.: Leucine-rich repeat kinase 2 associates with lipid rafts. Hum. Mol. Genet. 16, 678-690 (2007).
49. Pelech S: Dimerization in protein kinase signaling. J. Biol. 5, 12 (2006).
50. Kerkhoff E, Rapp U: The Ras-Raf relationship: an unfinished puzzle. Advances in Enzyme Regulation 41(1), 261-267 (2001).
51. Greggio E, Zambrano I, Kaganovich A et al.: The Parkinson's disease associated leucine rich repeat kinase 2 (LRRK2) is a dimer that undergoes intra-molecular autophosphorylation. J. Biol. Chem. 283(24), 16906-16914 (2008).
52. Dachsel JC, Taylor J, Mok SS et al.: Identification of potential protein interactors of Lrrk2. Parkinsonism Relat. Disord. 13(7), 382-385 (2008).
53. Deng J, Lewis PA, Greggio E et al.: Structure of the ROC domain from the Parkinson's disease-associated leucine-rich repeat kinase 2 reveals a dimeric GTPase. Proc. Natl Acad. Sci. USA 105, 1499-1504 (2008).
54. Toft M, Mata IF, Kachergus JM, Ross OA, Farrer MJ: LRRK2 mutations and parkinsonism. Lancet 365, 1229-1230 (2005).
55. Jaleel M, Nichols RJ, Deak M et al.: LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. Biochem. J. 405, 307-317 (2007).
56. Luzon-Toro B, Rubio de la Torre E, Delgado A, Perez-Tur J, Hilfiker S: Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation. Hum. Mol. Genet. 16, 2031-2039 (2007).
57. West AB, Moore DJ, Choi C et al.: Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity. Hum. Mol. Genet. 16, 223-232 (2007).
58. Lewis PA, Greggio E, Beilina A et al.: The R1441C mutation of LRRK2 disrupts GTP hydrolysis. Biochem. Biophys. Res. Commun. 357, 668-671 (2007).
59. Guo L, Gandhi PN, Wang W et al.: The Parkinson's disease-associated protein, leucine-rich repeat kinase 2 (LRRK2), is an authentic GTPase that stimulates kinase activity. Exp. Cell Res. 313, 3658-3670 (2007).
60. Ito G, Okai T, Fujino G et al.: GTP binding is essential to the protein kinase activity of LRRK2, a causative gene product for familial Parkinson's disease. Biochemistry 46, 1380-1388 (2007).
61. Smith WW, Pei Z, Jiang H et al.: Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. Proc. Natl Acad. Sci. USA 102, 18676-18681 (2005).
62. Plowey ED, Cherra SJ 3rd, Liu YJ, Chu CT: Role of autophagy in G2019S-LRRK2-associated neurite shortening in differentiated SH-SY5Y cells. J. Neurochem. 105, 1048-1056 (2008).
63. Burke RE: Inhibition of mitogen-activated protein kinase and stimulation of Akt kinase signaling pathways: two approaches with therapeutic potential in the treatment of neurodegenerative disease. Pharmacol. Ther. 114, 261-277 (2007).
64. Habig K, Walter M, Poths S, Riess O, Bonin M: RNA interference of LRRK2-microarray expression analysis of a Parkinson's disease key player. Neurogenetics 9, 83-94 (2008).
65. Paglini G, Kunda P, Quiroga S, Kosik K, Caceres A: Suppression of radixin and moesin alters growth cone morphology, motility, and process formation in primary cultured neurons. J. Cell. Biol. 143, 443-455 (1998).
66. Furutani Y, Matsuno H, Kawasaki M et al.: Interaction between telencephalin and ERM family proteins mediates dendritic filopodia formation. J. Neurosci. 27, 8866-8876 (2007).
67. Shin N, Jeong H, Kwon J et al.: LRRK2 regulates synaptic vesicle endocytosis. Exp. Cell Res. 314 (10), 2055-2065 (2008).
68. de Hoop MJ, Huber LA, Stenmark H et al.: The involvement of the small GTP-binding protein Rab5a in neuronal endocytosis. Neuron 13, 11-22 (1994).
69. Gandhi PN, Wang X, Zhu X, Chen SG, Wilson-Delfosse AL: The Roc domain of leucine-rich repeat kinase 2 is sufficient for interaction with microtubules. J. Neurosci. Res. 86(8), 1711-1720 (2008).
70. 2+/ calmodulin-dependent, cytoskeletal-associated protein kinase, with cell death-inducing functions that depend on its catalytic activity. EMBO J. 16, 998-1008 (1997).
71. Dachsel JC, Mata IF, Ross OA et al.: Digenic parkinsonism: investigation of the synergistic effects of PRKN and LRRK2. Neurosci. Lett. 410, 80-84 (2006).
72. Wang L, Xie C, Greggio E et al.: The chaperone activity of heat shock protein (Hsp)90 is critical for maintaining the stability of leucine-rich repeat kinase 2. J. Neurosci. 28, 3384-3391 (2008).
73. Sakaguchi-Nakashima A, Meif JY, Jin Y, Matsumoto K, Hisamoto N: LRK-1, a C. elegans PARK8-related kinase, regulates axonal-dendritic polarity of SV proteins. Curr. Biol, 17, 592-598 (2007).
74. Wolozin B. Saha S, Guillily M, Ferree A, Riley M: Investigating convergent actions of genes linked to familial Parkinson's disease. Neurodegener. Dis. 5, 182-185 (2008).
75. Lee SB, Kim W, Lee S, Chung J: Loss of LRRK2/PARK8 induces degeneration of dopaminergic neurons in Drosophila. Biochem. Biophys. Res. Commun. 358, 534-539 (2007).
76. Wang D, Tang B, Zhao G et al.: Dispensable role of Drosophila ortholog of LRRK2 kinase activity in survival of dopaminergic neurons. Mol. Neurodegener. 3, 3 (2008).
77. Liu Z, Wang X, Yu Y et al.: A Drosophila model for LRRK2-linked Parkinsonism. Proc. Natl Acad. Sci. USA 105, 2693-2698 (2008).
78. Marin I: Ancient origin of the Parkinson disease gene LRRK2. J. Mol. Evol. 67(1), 41-50 (2008).
79. Iaccarino C, Crosio C, Vitale C et al.: Apoptotic mechanisms in mutant LRRK2-mediated cell death. Hum. Mol. Genet. 16, 1319-1326 (2007).
80. Melrose HL, Kent CB, Taylor JP et al.: A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147, 1047-1058 (2007).
81. Doetsch F, Garcia-Verdugo JM, Alvarez-Buylla A: Cellular composition and three-dimensional organization of the subventricular germinal zone in the adult mammalian brain.J. Neurosci. 17, 5046-5061 (1997).
82. Mandairon N, Sacquet J, Jourdan F, Didier A: Long-term fate and distribution of newborn cells in the adult mouse olfactory bulb: influences of olfactory deprivation. Neuroscience 141, 443-451 (2006).
83. Saino-Saito S, Sasaki H, Volpe BT et al.: Differentiation of the dopaminergic phenotype in the olfactory system of neonatal and adult mice. J. Comp. Neurol. 479, 389-398 (2004).
84. Petreanu L, Alvarez-Buylla A: Maturation and death of adult-born olfactory bulb granule Neurons: role of olfaction. J. Neurosci. 22, 6106-6113 (2002).
85. Gheusi G, Cremer H, McLean H et al.: Importance of newly generated neurons in the adult olfactory bulb for odor discrimination. Proc. Natl Acad. Sci. USA 97, 1823-1828 (2000).
86. Berendse HW, Booij J, Francot CM et al.: Subclinical dopaminergic dysfunction in asymptomatic Parkinson's disease patients' relatives with a decreased sense of smell. Ann. Neurol. 50, 34-41 (2001).
87. Sobel N, Thomason ME, Stappen I et al.: An impairment in sniffing contributes to the olfactory impairment in Parkinson's disease. Proc. Natl Acad. Sci. USA 98, 4154-4159 (2001).
88. Braak H, Del Tredici K, Rub U et al.: Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
89. Winner B, Lie DC, Rockenstein E et al.: Human wild-type α-synuclein impairs neurogenesis. J. Neuropathol. Exp. Neurol. 63, 1155-1166 (2004).
90. Winner B, Rockenstein E, Lie DC et al.: Mutant α-synuclein exacerbates age-related decrease of neurogenesis. Neurobiol. Aging 29 (6), 913-925 (2008).
91. Hoglinger GU, Rizk P, Muriel MP et al.: Dopamine depletion impairs precursor cell proliferation in Parkinson disease. Nat. Neurosci. 7, 726-735 (2004).
92. Huisman E, Uylings HB, Hoogland PV: A 100% increase of dopaminergic cells in the olfactory bulb may explain hyposmia in Parkinson's disease. Mov. Disord. 19, 687-692 (2004).
93. Berg D: Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener. Dis. 5, 133-136 (2008).
94. Melrose HL, Kent CB, Taylor JP et al.: A comparative analysis of leucine-rich repeat kinase 2 (Lrrk2) expression in mouse brain and Lewy body disease. Neuroscience 147(4), 1047-1058 (2007).